Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Julphar
Chubb
Express Scripts
Colorcon
QuintilesIMS
Mallinckrodt
Deloitte
Johnson and Johnson
Daiichi Sankyo

Generated: May 22, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,122,566

« Back to Dashboard

Which drugs does patent 7,122,566 protect, and when does it expire?

Patent 7,122,566 protects SKELAXIN and is included in one NDA.

This patent has two patent family members in two countries.
Summary for Patent: 7,122,566
Title:Metaxalone products, method of manufacture, and method of use
Abstract:Disclosed herein is a method of using metaxalone. In one embodiment, the method comprises obtaining metaxalone from a container providing information that metaxalone affects the activity of a cytochrome p450 isozyme. In another embodiment, the method comprises informing a user that metaxalone affects the activity of a cytochrome p450 isozyme. Also included are articles of manufacture comprising a container containing a dosage form of metaxalone, wherein the container is associated with published material informing that metaxalone affects activity of a cytochrome p450 isozyme. Also disclosed are a method of treatment and a method of manufacturing a metaxalone product.
Inventor(s): Du; Jie (Lansdale, PA), Roberts; Richard H. (Lakewood, NJ)
Assignee: Mutual Pharmaceutical Company, Inc. (Philadelphia, PA)
Application Number:11/364,468
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,122,566
Patent Claim Types:
see list of patent claims
Use;

Drugs Protected by US Patent 7,122,566

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
King Pharms SKELAXIN metaxalone TABLET;ORAL 013217-003 Aug 30, 2002 AB RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF MUSCULOSKELETAL CONDITIONS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,122,566

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
7,378,434 Metaxalone products, method of manufacture, and method of use ➤ Sign Up
8,168,664 Metaxalone products, method of manufacture, and method of use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Boehringer Ingelheim
AstraZeneca
Merck
Covington
Colorcon
Federal Trade Commission
Medtronic
Accenture
Healthtrust

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.